MILIP Binding to TRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2024 Apr 9

PMID 38593213

Authors

Si Min Zheng

Yu Chen Feng

Qin Zhu

Ruo Qi Li

Qian Qian Yan

Liu Teng

Yi Meng Yue

Man Man Han

Kaihong Ye

Sheng Nan Zhang

Teng Fei Qi

Cai Xia Tang

Xiao Hong Zhao

Yuan Yuan Zhang

Liang Xu

Ran Xu

Jun Xing

Mark Baker

Tao Liu

Rick F Thorne

Lei Jin

Thomas Preiss

Xu Dong Zhang

Shundong Cang

Jin Nan Gao

Affiliations

Soon will be listed here.

Abstract

Significance: LncRNA MILIP plays a key role in supporting protein production in TNBC by forming complexes with tRNAs and eEF1α1, which confers sensitivity to combined MILIP targeting and protein synthesis inhibitors.

References

Wang P, Teng L, Feng Y, Yue Y, Han M, Yan Q . The N-Myc-responsive lncRNA MILIP promotes DNA double-strand break repair through non-homologous end joining. Proc Natl Acad Sci U S A. 2022; 119(49):e2208904119. PMC: 9894261. DOI: 10.1073/pnas.2208904119. View

Hu G, Lou Z, Gupta M . The long non-coding RNA GAS5 cooperates with the eukaryotic translation initiation factor 4E to regulate c-Myc translation. PLoS One. 2014; 9(9):e107016. PMC: 4157848. DOI: 10.1371/journal.pone.0107016. View

Bianchini G, De Angelis C, Licata L, Gianni L . Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2021; 19(2):91-113. DOI: 10.1038/s41571-021-00565-2. View

Kovalski J, Kuzuoglu-Ozturk D, Ruggero D . Protein synthesis control in cancer: selectivity and therapeutic targeting. EMBO J. 2022; 41(8):e109823. PMC: 9016353. DOI: 10.15252/embj.2021109823. View

Jiang C, Croft A, Tseng H, Guo S, Jin L, Hersey P . Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. Oncogene. 2013; 33(20):2577-88. DOI: 10.1038/onc.2013.237. View

Lim K, Yokota T . Invention and Early History of Gapmers. Methods Mol Biol. 2020; 2176:3-19. DOI: 10.1007/978-1-0716-0771-8_1. View

Miller I, Min M, Yang C, Tian C, Gookin S, Carter D . Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence. Cell Rep. 2018; 24(5):1105-1112.e5. PMC: 6108547. DOI: 10.1016/j.celrep.2018.06.110. View

Mills A, Gago F . On the Need to Tell Apart Fraternal Twins eEF1A1 and eEF1A2, and Their Respective Outfits. Int J Mol Sci. 2021; 22(13). PMC: 8268798. DOI: 10.3390/ijms22136973. View

Teng L, Feng Y, Guo S, Wang P, Qi T, Yue Y . The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis. Nat Commun. 2021; 12(1):3734. PMC: 8213729. DOI: 10.1038/s41467-021-24099-4. View

10.

Dibra D, Moyer S, El-Naggar A, Qi Y, Su X, Lozano G . Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci U S A. 2023; 120(34):e2308807120. PMC: 10450424. DOI: 10.1073/pnas.2308807120. View

11.

Gandhi V, Plunkett W, Cortes J . Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014; 20(7):1735-40. PMC: 4048124. DOI: 10.1158/1078-0432.CCR-13-1283. View

12.

Narayan P, Wahby S, Gao J, Amiri-Kordestani L, Ibrahim A, Bloomquist E . FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1. Clin Cancer Res. 2020; 26(10):2284-2289. DOI: 10.1158/1078-0432.CCR-19-3545. View

13.

Miller D, Thomas S, Islam A, Muench D, Sedoris K . c-Myc and cancer metabolism. Clin Cancer Res. 2012; 18(20):5546-53. PMC: 3505847. DOI: 10.1158/1078-0432.CCR-12-0977. View

14.

Shtraizent N, Matsui H, Polotskaia A, Bargonetti J . Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. Int J Environ Res Public Health. 2015; 13(1):ijerph13010022. PMC: 4730413. DOI: 10.3390/ijerph13010022. View

15.

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

16.

Mukai T, Vargas-Rodriguez O, Englert M, Tripp H, Ivanova N, Rubin E . Transfer RNAs with novel cloverleaf structures. Nucleic Acids Res. 2017; 45(5):2776-2785. PMC: 5389517. DOI: 10.1093/nar/gkw898. View

17.

Cortesi L, Rugo H, Jackisch C . An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021; 16(3):255-282. PMC: 8105250. DOI: 10.1007/s11523-021-00796-4. View

18.

Karakas D, Ozpolat B . The Role of LncRNAs in Translation. Noncoding RNA. 2021; 7(1). PMC: 8005997. DOI: 10.3390/ncrna7010016. View

19.

Abbas W, Kumar A, Herbein G . The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections. Front Oncol. 2015; 5:75. PMC: 4387925. DOI: 10.3389/fonc.2015.00075. View

20.

Krahn N, Fischer J, Soll D . Naturally Occurring tRNAs With Non-canonical Structures. Front Microbiol. 2020; 11:596914. PMC: 7609411. DOI: 10.3389/fmicb.2020.596914. View